Literature DB >> 23957539

Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.

Kristina Langholz Kristensen1, Ulrik Bak Dragsted.   

Abstract

The ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23957539     DOI： 10.3109/00365548.2013.822093

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  6 in total

1.  Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

Authors:  Sean R Marcsisin; Jason C Sousa; Gregory A Reichard; Diana Caridha; Qiang Zeng; Norma Roncal; Ronan McNulty; Julio Careagabarja; Richard J Sciotti; Jason W Bennett; Victor E Zottig; Gregory Deye; Qigui Li; Lisa Read; Mark Hickman; N P Dhammika Nanayakkara; Larry A Walker; Bryan Smith; Victor Melendez; Brandon S Pybus
Journal:  Malar J       Date:  2014-01-03       Impact factor: 2.979

2.  Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax.

Authors:  D D Rajgor; N J Gogtay; V S Kadam; M M Kocharekar; M S Parulekar; S S Dalvi; A B Vaidya; N A Kshirsagar
Journal:  Malar Res Treat       Date:  2014-09-10

3.  In silico Identification and Validation of a Linear and Naturally Immunogenic B-Cell Epitope of the Plasmodium vivax Malaria Vaccine Candidate Merozoite Surface Protein-9.

Authors:  Rodrigo Nunes Rodrigues-da-Silva; João Hermínio Martins da Silva; Balwan Singh; Jianlin Jiang; Esmeralda V S Meyer; Fátima Santos; Dalma Maria Banic; Alberto Moreno; Mary R Galinski; Joseli Oliveira-Ferreira; Josué da Costa Lima-Junior
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

4.  Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants.

Authors:  Rodrigo Nunes Rodrigues-da-Silva; Isabela Ferreira Soares; Cesar Lopez-Camacho; João Hermínio Martins da Silva; Daiana de Souza Perce-da-Silva; Antônio Têva; Antônia Maria Ramos Franco; Francimeire Gomes Pinheiro; Lana Bitencourt Chaves; Lilian Rose Pratt-Riccio; Arturo Reyes-Sandoval; Dalma Maria Banic; Josué da Costa Lima-Junior
Journal:  Front Immunol       Date:  2017-02-07       Impact factor: 7.561

5.  The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites.

Authors:  Medard Ernest; Carol Hunja; Yuka Arakura; Yohei Haraga; Hussein M Abkallo; Weiguang Zeng; David C Jackson; Brendon Chua; Richard Culleton
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-10-23       Impact factor: 4.077

6.  Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.

Authors:  Monpat Chamnanphon; Andrea Gaedigk; Apichaya Puangpetch; Ekawat Pasomsub; Wasun Chantratita; Rhea J Longley; Jetsumon Sattabongkot; Pajaree Chariyavilaskul; Chonlaphat Sukasem
Journal:  Pharmgenomics Pers Med       Date:  2020-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.